Under the Paperwork Reduction Act of 1995, no persons are n Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

required to respond to a collection of	of inition ration, unless it contains a valid Civid	COMBO HUMBO.
,	Complete if Known	3
Application Number	99/919,590	
Filing Date	July 30, 2001	3
First Named Inventor	/ Parks, Thomas P.	ō
Group Art Unit	1614	<u> </u>
Examiner Name		23
Attorney Docket Number	010692-005431US	8

					U.S. PATEN	T DOCUM	ENTS	
Ē	Examiner Initials	Cite No.1	U.S. Patent Docu Number Kind C (if known)	ode ²	Name of Patentee or of Cited Decun	Applicant nent	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	² / ₂	1	4,945,084		Packman			
50	ווי וו	2	5,196,405		Packman			11.0
		3	5,234,947	\bot	Cherksey	$H \rightarrow A$	L sure	- Me
	\$	4	5,447,947		Campbell	/-/	1000	
ne	W. C.	5	5,478,814		Packman /			Lov Phenene
7		6	5,492,911	$\overline{}$	Stief			200.
l		7	5,576,290		Hadley			
ı		8	5,595,753		Hechtman /	0		
l		9	5,693,676		Gorfine /			
		10	5,854,291		Laughlin, et al.			
		11	5,874,437		Garvey, et al.			
		12	5,932,538		Garvey, et al.			
		13	5,948,762		Garfield, et al.			
		14	5,994,294		Garvey, et al.			
		15	6,117,877		Fogel			
		16	6,159,944		Fogel			
		17	5,721,215		/Aoki, et al.			
		18	5,562,899		Gerber			
		19	5,437,291	/	Pasricha, et al.	<u> </u>		
L		20	5,858,371		Singh, et al.			

			/	FOREIG	N PATENT DOCUME	NTS		
Examiner Initials*	Cite No.1	For Office ³	reign Patent Do Number⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	21	wo	95 ⁰⁶⁴⁶⁶ A		Lubowsky, KOREN LABORATORIES PTY. LTD.			
	22	wo	97/27749 A		Garvey, NITROMED INC.			
	. 23	wo /	98 19672 A		Garvey, NITROMED INC.			

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are n

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

	(ase as many	3110013	43 1100	.03347
<u> </u>			, 4	

or information unless it contains a valid Civils o	
Complete if Known	12
09/919,590	
July 30, 2001	
Parks, Thomas P.	Ç
1614	7/4
	- 6
010692-005431US	
	Complete if Known 09/919,590 July 30, 2001 Parks, Thomas P. 1614

FOREIGN PATENT DOCUMENTS								
		For	eign Patent Do	cument		Date of	Pages, Columns,	
Examiner Initials*	Cite No.1	Office ³	Number⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Publication of Cited Document MM-DD-YYYY	Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
****	24	wo	98 27971 A		M. Kamm et al.			



Examiner Signature	Date Considered	_

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0112 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO					Complete if Known	
INFORMATION DISCLOSURE				Application Number	09/919,590	וב
INFORMATION DISCLOSURE				Filing Date	July 30, 2001	Ξ.
STATEMENT BY APPLICANT				First Named Inventor	Parks, Thomas P.	99
				Group Art Unit	1614	2/0
(use as many sheets as necessary)				Examiner Name		06
Sheet	3	of	4	Attorney Docket Number	010692-005431US	

Examiner Initials * Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. 25 BAIRD, A. A., et al., Br. J. Pharmacol. 100, 329-335 (1990) 26 CARAPETI, E. A., et al., Gut 45:719-722 (1999) 27 GLAVIND, E.B., et al., Am. J. Physiol., 272(5, Pt. 1), G1075-G1082 (1997) 28 GORFINE, S. R., Diseases of the Colon & Rectum, XP-002084601 *Treatment of Benign Anal Disease with Topical Nitroglycerin*, V38, Number 5, pp. 453-457 (1995) 29 GOYAL, R. K., et al., J. Clin. Invest., 52(2), 337-41 (1973) 30 HEYDEN, B., et al., Neurourol. Urodyn. 14(2), 153-68 (1995) 31 RAE, MG, et al., J Physiol, Jun 1;493 (Pt 2):517-27 (1996) 32 RATTAN, S., et al., American Physiological Society, G107-G112 (1992)	
26 CARAPETI, E A, et al., <i>Gut</i> 45:719-722 (1999) 27 GLAVIND, E.B., et al., <i>Am. J. Physiol.</i> , 272(5, Pt. 1), G1075-G1082 (1997) 28 GORFINE, S. R., <i>Diseases of the Colon & Rectum</i> , XP-002084601 "Treatment of Benign Anal Disease with Topical Nitroglycerin", V38, Number 5, pp. 453-457 (1995) 29 GOYAL, R. K., et al., <i>J. Clin. Invest.</i> , 52(2), 337-41 (1973) 30 HEYDEN, B., et al., <i>Neurourol. Urodyn.</i> 14(2), 153-68 (1995) 31 RAE, MG, et al., <i>J Physiol</i> , Jun 1;493 (Pt 2):517-27 (1996)	T²
3 2001 65 27 GLAVIND, E.B., et al., Am. J. Physiol., 272(5, Pt. 1), G1075-G1082 (1997) 28 GORFINE, S. R., Diseases of the Colon & Rectum, XP-002084601 "Treatment of Benign Anal Disease with Topical Nitroglycerin", V38, Number 5, pp. 453-457 (1995) 29 GOYAL, R. K., et al., J. Clin. Invest., 52(2), 337-41 (1973) 30 HEYDEN, B., et al., Neurourol. Urodyn. 14(2), 153-68 (1995) 31 RAE, MG, et al., J Physiol, Jun 1;493 (Pt 2):517-27 (1996)	
28 GORFINE, S. R., <i>Diseases of the Colon & Rectum</i> , XP-002084601 "Treatment of Benign Anal Disease with Topical Nitroglycerin", V38, Number 5, pp. 453-457 (1995) 29 GOYAL, R. K., et al., <i>J. Clin. Invest.</i> , 52(2), 337-41 (1973) 30 HEYDEN, B., et al., <i>Neurourol. Urodyn.</i> 14(2), 153-68 (1995) 31 RAE, MG, et al., <i>J Physiol</i> , Jun 1;493 (Pt 2):517-27 (1996)	
29 GOYAL, R. K., et al., <i>J. Clin. Invest.</i> , 52(2), 337-41 (1973) 30 HEYDEN, B., et al., <i>Neurourol. Urodyn.</i> 14(2), 153-68 (1995) 31 RAE, MG, et al., <i>J Physiol</i> , Jun 1;493 (Pt 2):517-27 (1996)	
30 HEYDEN, B., et al., <i>Neurourol. Urodyn.</i> 14(2), 153-68 (1995) 31 RAE, MG, et al., <i>J Physiol</i> , Jun 1;493 (Pt 2):517-27 (1996)	
31 RAE, MG, et al., <i>J Physiol</i> , Jun 1;493 (Pt 2):517-27 (1996)	
10.2, 110, 0.01, 0.7 11,000 (1.12),011 21 (1000)	
32 RATTAN, S., et al., American Physiological Society, G107-G112 (1992)	
33 SALAPATEK, A M, et al., Br J Pharmacol Mar;123(6):1055-64 (1998)	
34 SALAPAETEK, A M et al., Am J. Physiol., 274(4, Pt. 1), C1145-C1157 (1998)	
35 SZILVASSY, Z., et al., <i>Pharmacol. Res.</i> 36(2), 129-133 (1997)	
36 JP 10-1441 TENDO SEIYAKU KK (TEND-N), Derwent Patent Summary (1998)	
WINQUIST, R. J., et al. Journal of Pharmacology and Experimental Therapeutics, Vol. 248, No. 1 pp. 149-156 (1989)	
BENOWITZ, N. L., "Antihypertensive Agents", Basic & Clinical Pharmacol., Edited by Katzung, Appleton & Lange, pp. 161-162, 1995	
BOUSHEY, H. A., "Bronchodilators & Other Agents Used in Asthma", Basic & Clinical Pharmacol., Edited by Katzung, Appleton & Lange, pp. 310-314, 1995	
SHARP, F. R., "Patient Selection and Treatment Modalities for Chronic Anal Fissure", Am. J. Surg., Vol. 171, No. 5, pp. 512-515, 1996	

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

WC 9031949 v1

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO

DEC 0 3 2001

PTO/SB/08B (08-0971-Approved for use through 10/31/2002. OMB 0651-00 J.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCEL

Under the Paperwork Reduction Act of 1999 repersons are required to respond to a collection of information unless it contains a valid OMB control number PANEN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

Todalisa en la concentra en la concentra en	THOTTEGOT GROSS IT CONTRAINS OF TODAY OF THE	001101110111001
Metr	Complete if Known	F
Application Number	09/919,590	
Filing Date	July 30, 2001	
First Named Inventor	Parks, Thomas P.	- 6
Group Art Unit	1614	120
Examiner Name		E
Attorney Docket Number	010692-005431US	

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
	41	KUBOTA, et al., "Membrane properties and the neuro-effector", 11/1998, J. Smooth Muscle Res., Vol. 34, pp. 173-184				
	42	BOUVIER, et al., "Nervous control of the internal anal sphincter", 12/1981, J. Phisiol., Vol. 310, pp. 457-469.				
	43	YAMATO, et al., "Role of Alpha adrenocepters in opossum internal anal", abstract, <i>J. Clin. Invest.</i> , 1990, Vol. 86(2), pp. 424-429				

WC 9031949 v1

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.